PL2506840T3 - Zastosowania inhibitorów czynnika indukowalnego niedotlenieniem - Google Patents

Zastosowania inhibitorów czynnika indukowalnego niedotlenieniem

Info

Publication number
PL2506840T3
PL2506840T3 PL10834883T PL10834883T PL2506840T3 PL 2506840 T3 PL2506840 T3 PL 2506840T3 PL 10834883 T PL10834883 T PL 10834883T PL 10834883 T PL10834883 T PL 10834883T PL 2506840 T3 PL2506840 T3 PL 2506840T3
Authority
PL
Poland
Prior art keywords
hypoxia
inducible factor
factor inhibitors
inhibitors
inducible
Prior art date
Application number
PL10834883T
Other languages
English (en)
Inventor
Yang Liu
Yin Wang
Yan Liu
Sami N. Malek
Pan ZENG
Original Assignee
OncoC4, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoC4, Inc. filed Critical OncoC4, Inc.
Publication of PL2506840T3 publication Critical patent/PL2506840T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10834883T 2009-12-04 2010-06-25 Zastosowania inhibitorów czynnika indukowalnego niedotlenieniem PL2506840T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26685609P 2009-12-04 2009-12-04
EP10834883.0A EP2506840B1 (en) 2009-12-04 2010-06-25 Uses of hypoxia-inducible factor inhibitors
PCT/US2010/039910 WO2011068563A1 (en) 2009-12-04 2010-06-25 Uses of hypoxia-inducible factor inhibitors

Publications (1)

Publication Number Publication Date
PL2506840T3 true PL2506840T3 (pl) 2021-10-11

Family

ID=44115219

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10834883T PL2506840T3 (pl) 2009-12-04 2010-06-25 Zastosowania inhibitorów czynnika indukowalnego niedotlenieniem

Country Status (15)

Country Link
US (7) US9427413B2 (pl)
EP (2) EP3892264A3 (pl)
CN (2) CN102791260A (pl)
CA (1) CA2782527C (pl)
CY (1) CY1125365T1 (pl)
DK (1) DK2506840T3 (pl)
ES (1) ES2864743T3 (pl)
HR (1) HRP20210537T1 (pl)
HU (1) HUE053793T2 (pl)
LT (1) LT2506840T (pl)
PL (1) PL2506840T3 (pl)
PT (1) PT2506840T (pl)
SI (1) SI2506840T1 (pl)
SM (1) SMT202100234T1 (pl)
WO (1) WO2011068563A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210537T1 (hr) 2009-12-04 2021-05-14 Oncoimmune Inc. Upotreba inhibitora faktora induciranog hipoksijom
CN103007293B (zh) * 2012-12-30 2014-04-02 中国人民解放军第三军医大学第一附属医院 具有靶向性的多肽-基因复合物及其制备方法和应用
CA2995582A1 (en) 2015-08-19 2017-02-23 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
SG11201803915UA (en) 2015-11-10 2018-06-28 Childrens Research Institute Childrens National Medical Center Echinomycin formulation, method of making and method of use thereof
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
RU2020102908A (ru) 2017-06-26 2021-07-27 Лунелла Байотек, Инк. Митокетосцины: митохондриальная терапия, нацеленная на кетоновый метаболизм в раковых клетках
CN110669871A (zh) * 2019-10-17 2020-01-10 河北森朗生物科技有限公司 一种慢病毒转导滴度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643871A (en) 1993-11-23 1997-07-01 Bristol-Meyers Squibb Company Antitumor antibiotics
US6416956B1 (en) 1999-08-13 2002-07-09 George Washington University Transcription factor, BP1
AU2002231223A1 (en) 2000-10-26 2002-05-06 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
CN1233844C (zh) * 2003-09-05 2005-12-28 上海第二医科大学附属瑞金医院 HIF－1α在治疗白血病药物的筛选中的应用
EP2316832B1 (en) * 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
EP1874824A4 (en) * 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
WO2007130037A1 (en) * 2006-05-02 2007-11-15 Emory University Hif-1 inhibitors and methods of use thereof
US20080063642A1 (en) 2006-08-02 2008-03-13 Adelman Daniel C Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
CA2683973A1 (en) * 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
US7867492B2 (en) * 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
HRP20210537T1 (hr) 2009-12-04 2021-05-14 Oncoimmune Inc. Upotreba inhibitora faktora induciranog hipoksijom

Also Published As

Publication number Publication date
US20170239315A1 (en) 2017-08-24
US20200147167A1 (en) 2020-05-14
SI2506840T1 (sl) 2021-08-31
PT2506840T (pt) 2021-04-27
DK2506840T3 (da) 2021-04-12
WO2011068563A1 (en) 2011-06-09
HRP20210537T1 (hr) 2021-05-14
US20180177841A1 (en) 2018-06-28
US9623070B2 (en) 2017-04-18
CN102791260A (zh) 2012-11-21
CN109224064A (zh) 2019-01-18
US20190255140A1 (en) 2019-08-22
US9427413B2 (en) 2016-08-30
CY1125365T1 (el) 2024-02-16
US20120264697A1 (en) 2012-10-18
LT2506840T (lt) 2021-06-25
EP3892264A3 (en) 2021-12-08
US20210161991A1 (en) 2021-06-03
US20170035832A1 (en) 2017-02-09
EP2506840A4 (en) 2013-07-03
HUE053793T2 (hu) 2021-07-28
EP2506840A1 (en) 2012-10-10
EP3892264A2 (en) 2021-10-13
SMT202100234T1 (it) 2021-05-07
ES2864743T3 (es) 2021-10-14
CA2782527A1 (en) 2011-06-09
US9877998B2 (en) 2018-01-30
EP2506840B1 (en) 2021-01-06
CA2782527C (en) 2019-09-17

Similar Documents

Publication Publication Date Title
ZA201700326B (en) Inhibitors of beta-secretase
GB2498145B (en) Releasable corrosion inhibitors
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
EP2576552A4 (en) BENZOQUINOLONE INHIBITORS OF VMAT2
ZA201206456B (en) Uses of dgati inhibitors
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
SMT202100234T1 (it) Usi di inibitori di fattori inducibili da ipossia
EP2519508A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
IL215645A0 (en) Inhibitors of cognitive decline
IL217833A0 (en) Inhibitors of cognitive decline
GB0901898D0 (en) Dual calpain-ros inhibitors
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
IL217756A0 (en) Inhibitors of jnk
SI2411376T1 (sl) INHIBITORJI NF-kB
GB0901900D0 (en) Dual calpain-ros inhibitors
IL215486A0 (en) Compositions of cholinesterase inhibitors
GB0908609D0 (en) New use of isoQC inhibitors
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
GB0903651D0 (en) Inhibitors of glyoxalase
GB0915927D0 (en) Novel inhibitors
GB0903650D0 (en) Glyoalase inhibitors
GB0902661D0 (en) Inhibitors
GB0921086D0 (en) Inhibitor of inflammatory conditions
GB0912526D0 (en) Inhibitor of inflammatory conditions
GB201003502D0 (en) Novel inhibitors